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IMPORTANCE Deprescribing of antihypertensive medications is recommended for some older
patients with polypharmacy and multimorbidity when the benefits of continued treatment
may not outweigh the harms.
OBJECTIVE This study aimed to establish whether antihypertensive medication reduction is
possible without significant changes in systolic blood pressure control or adverse events
during 12-week follow-up.
DESIGN, SETTING, AND PARTICIPANTS The Optimising Treatment for Mild Systolic
Hypertension in the Elderly (OPTIMISE) study was a randomized, unblinded, noninferiority
trial conducted in 69 primary care sites in England. Participants, whose primary care
physician considered them appropriate for medication reduction, were aged 80 years and
older, had systolic blood pressure lower than 150 mm Hg, and were receiving at least 2
antihypertensive medications were included. Participants enrolled between April 2017 and
September 2018 and underwent follow-up until January 2019.
INTERVENTIONS Participants were randomized (1:1 ratio) to a strategy of antihypertensive
medication reduction (removal of 1 drug [intervention], n = 282) or usual care (control,
n = 287), in which no medication changes were mandated.
MAIN OUTCOMES AND MEASURES The primary outcome was systolic blood pressure lower
than 150 mm Hg at 12-week follow-up. The prespecified noninferiority margin was a relative
risk (RR) of 0.90. Secondary outcomes included the proportion of participants maintaining
medication reduction and differences in blood pressure, frailty, quality of life, adverse effects,
and serious adverse events.
RESULTS Among 569 patients randomized (mean age, 84.8 years; 276 [48.5%] women;
median of 2 antihypertensive medications prescribed at baseline), 534 (93.8%) completed
the trial. Overall, 229 (86.4%) patients in the intervention group and 236 (87.7%) patients in
the control group had a systolic blood pressure lower than 150 mm Hg at 12 weeks (adjusted
RR, 0.98 [97.5% 1-sided CI, 0.92 to ]). Of 7 prespecified secondary end points, 5 showed no
significant difference. Medication reduction was sustained in 187 (66.3%) participants at 12
weeks. Mean change in systolic blood pressure was 3.4 mm Hg (95% CI, 1.1 to 5.8 mm Hg)
higher in the intervention group compared with the control group. Twelve (4.3%) participants
in the intervention group and 7 (2.4%) in the control group reported at least 1 serious adverse
event (adjusted RR, 1.72 [95% CI, 0.7 to 4.3]).
CONCLUSIONS AND RELEVANCE Among older patients treated with multiple antihypertensive
medications, a strategy of medication reduction, compared with usual care, was noninferior
with regard to systolic blood pressure control at 12 weeks. The findings suggest
antihypertensive medication reduction in some older patients with hypertension is not
associated with substantial change in blood pressure control, although further research is
needed to understand long-term clinical outcomes.
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H igh blood pressure is the leading modifiable riskfactor for cardiovascular disease1 and the mostcommon comorbid condition in older people
with multimorbidity.2 Antihypertensive treatment pre-
vents stroke and cardiovascular disease in older high-risk
patients,3,4 and approximately half of individuals aged 80
years or older are prescribed therapy.5 However, previous
trials such as the Systolic Blood Pressure Intervention
(SPRINT)4 trial have been shown to represent as few as one-
third of older individuals in the general population,6 and
there is debate about the extent to which these data should
be applied to frail patients with multimorbidity.7 Evidence
from observational studies suggests that lower blood pres-
sure and multiple antihypertensive prescriptions may be
harmful in some older patients with polypharmacy and
multimorbidity.8-10
Guidelines recommend using clinical judgement when pre-
scribing in frail older patients,11,12 emphasizing a personal-
ized approach to care that might include attempts to improve
quality of life through deprescribing.13-15 However, these guide-
lines are largely based on expert opinion and are vague on how
to achieve medication reduction due to a lack of evidence, high-
lighting the need for research in this area.14
Few randomized clinical trials have considered the
safety and efficacy of antihypertensive medication reduction
in routine clinical practice.15 In older patients with multi-
morbidity and controlled blood pressure (<150/90 mm Hg),
there are advantages and disadvantages to continuing
treatment.8-10 For patients whose physicians determine
that potential risks of continuing treatment outweigh ben-
efits, there is no evidence to guide medication reduction.
This trial examined a structured approach to antihyperten-
sive medication reduction in older patients with multimor-
bidity and controlled systolic hypertension prescribed 2 or
more antihypertensives. The trial aimed to establish
whether partial medication reduction is possible without
clinically significant changes in blood pressure control,
frailty, quality of life, adverse effects, serious adverse
events, and change in systolic and diastolic blood pressure
after 12 weeks of follow-up.
Methods
The study protocol can be found in Supplement 1. The statis-
tical analysis plan can be found in Supplement 2. The proto-
col for this trial has also been published in detail elsewhere.16
Study Design
The Optimising Treatment for Mild Systolic Hypertension in
the Elderly (OPTIMISE) trial used a primary care–based, ran-
domized, unblinded, parallel group, noninferiority design.
Participants were individually randomized (1:1 ratio) to a
strategy of antihypertensive medication reduction (interven-
tion group) or usual care (control group) and followed up for
12 weeks. The study was approved by an NHS Research Eth-
ics Committee (South Central-Oxford A; ref 16/SC/0628) and
the Medicines and Healthcare Products Regulatory Agency
(MHRA; ref 21584/0371/001-0001). All participants provided
written informed consent.
Participants and Setting
This study was conducted in primary care sites across
South and Central England. Participants were aged 80 years
and older, had a baseline systolic blood pressure lower than
150 mm Hg, and were prescribed 2 or more antihypertensive
treatments for at least 12 months. Detailed inclusion and ex-
clusion criteria are provided in eTable 1 in Supplement 3. At
the beginning of the trial, primary care physicians who con-
ducted recruitment were educated about the latest guide-
lines and evidence from randomized clinical trials. The gen-
eralizability of these trials was discussed and physicians were
asked to only enroll patients who, in their opinion, might po-
tentially benefit from medication reduction due to 1 or more
of the following existing characteristics: polypharmacy, co-
morbidity, nonadherence or dislike of medicines, or frailty. This
clinical judgement was considered important given the cur-
rent lack of evidence as to who should be targeted for medi-
cation reduction. Patients with a history of heart failure due
to left ventricular dysfunction or myocardial infarction or stroke
in the preceding 12 months, secondary hypertension, or lack-
ing in capacity to consent were excluded. Participants were
identified from searches of electronic health records in par-
ticipating sites and sent letters of invitation. Those express-
ing an interest attended a screening appointment.
Randomization and Masking
The screening appointment comprised a study explanation by
the primary care physician, obtainment of informed consent,
and eligibility assessment. Participants underwent baseline as-
sessments and were randomized (1:1 ratio) to one of the 2 study
groups using a nondeterministic minimization algorithm, with
minimization designed to balance site and baseline SBP via a
fully validated web-based password-protected system. The first
3 participants were allocated using simple randomization with
subsequent participants allocated with a probability at 0.8 to
ensure balance across the groups.
Investigators and participants were unaware of treatment
allocation prior to consent and baseline assessments.
Key Points
Question Among older adults taking multiple antihypertensive
medications, is a strategy of antihypertensive medication
reduction noninferior to usual care with regard to short-term
blood pressure control?
Findings In this randomized clinical trial that included 569
patients aged 80 years and older, the proportion with systolic
blood pressure lower than 150 mm Hg at 12 weeks was 86.4% in
the intervention group and 87.7% in the control group (adjusted
relative risk, 0.98), a difference that met the noninferiority margin
of a relative risk of 0.90.
Meaning The findings suggest antihypertensive medication
reduction can be achieved without substantial change in blood
pressure control in some older patients with hypertension.
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The trial used an unblinded design with patients and investiga-
tors not masked to randomization group. Prespecified statisti-
cal analyses were performed blind to participant allocation.
Procedures
Participating primary care physicians reviewed each patient’s
medication regimen prior to baseline and decided which
antihypertensive drug would be removed if the participant
was randomized to the medication reduction group of the
trial. Primary care physicians were given a medication reduc-
tion algorithm (eFigure 1 in Supplement 3) to assist with this
decision. Since combination pills for antihypertensive treat-
ment are rarely used in the United Kingdom, no specific guid-
ance was given on how these should be handled. Following
medication reduction, primary care physicians were asked to
follow a safety monitoring algorithm (eFigure 2 in Supple-
ment 3) including through the 4-week follow-up. They were
asked to reinstate treatment if systolic blood pressure was
found to be above 150 mm Hg or diastolic blood pressure was
above 90 mm Hg for more than 1 week, adverse events
occurred, or signs of accelerated hypertension developed. All
participants randomized to the medication reduction group
were given the option to self-monitor their blood pressure.
Some participants chose to accept this offer, but rates of self-
monitoring among the intervention group were not recorded
systematically. All other clinical care continued as usual.
Participants who were randomized to the control group
followed usual clinical care, in which they continued to take
all antihypertensive medications as prescribed, with no
medication changes mandated. All participants were
followed-up at 12 weeks. All data were collected by a research
facilitator or nurse in clinics held at baseline, 4-week safety
visit (for the intervention group only), and 12-week follow-
up. At baseline, assessments of functional independence
were undertaken using the Modified Rankin scale,17 and cog-
nitive function was assessed using the Montreal Cognitive
Assessment.18 The ethnicity of each participant was recorded
at baseline to better characterize the sample population.
Ethnicity was self-determined by the participant using a
questionnaire containing standard fixed ethnic categories.19
For analysis, those identifying as White British or White other
were classified as white, and all other participants were clas-
sified as nonwhite/unknown.
Outcome Measures
The primary outcome was the relative risk of systolic blood
pressure control (<150 mm Hg; defined by UK National Insti-
tute for Health and Care Excellence as the target blood pres-
sure for those older than 80 years) between groups at
12-week follow-up. Blood pressure was measured using the
clinically validated BpTRU blood pressure monitor.20 Read-
ings were taken in the left arm, using an appropriately sized
cuff, after participants had been seated for at least 5 minutes
of rest. Systolic blood pressure was estimated from the mean
of the second and third readings.
All prespecified secondary outcomes are reported in this
article, with the exception of one to determine how the base-
line characteristics of the study population relate to those of
previous trials3,4 (which will be reported separately). Second-
ary outcomes were the proportion of participants in the inter-
vention group who maintained medication reduction and
between-group differences in frailty, quality of life, adverse
effects, serious adverse events, and change in systolic and
diastolic blood pressure over 12 weeks. Frailty was defined
using the Frailty index (54 items; range, 0 [fit] to 1 [frail]),21
the Electronic Frailty Index (36 items; range, 0 [fit] to 1 [frail];
estimated using data from electronic health records),22 and
the Morley FRAIL scale (5 components; range, 0 [robust
health] to 4 [frail]; captured via questionnaire).23 Quality of
life was measured using the EuroQoL 5 Dimensions 5 Levels
questionnaire (EQ-5D-5L).24 Data from this questionnaire
were analyzed using the cross-walk approach, which trans-
lates the scores for the 5 EQ-5D-5L items into a single index
value and visual analogue scale (VAS; range, 0 [worst health]
to 100 [best health]).24 Adverse effects to medication were
captured using the Revised Illness Perception Questionnaire
for hypertension.25 Adverse effects included 24 symptoms,
and these were summed to give the number of symptoms
reported. Serious adverse events were defined as those
resulting in death or considered life threatening, required
inpatient hospitalization or prolonged existing hospitaliza-
tion, resulted in persistent or significant disability or incapac-
ity, or were classified as other medical events considered to
be serious because they put the participant at risk of one of
the previously mentioned consequences or required inter-
vention to prevent occurrence.
Further post hoc outcomes were specified after viewing
the initial results to better understand the effect of the medi-
cation reduction intervention. These were mean difference in
change in number of antihypertensive medication prescrip-
tions, the proportion of patients with no increase in systolic
blood pressure during follow-up, mean difference in health re-
source use (primary care consultations and hospital atten-
dance), and difference in adverse events (nonserious) during
12-week follow-up. To better understand any observed differ-
ences in adverse events, each event was categorized by the
treating clinician as to whether or not it was possibly related
to medication reduction and classified by the research team
according to definitions of disease (online version, Interna-
tional Classification of Diseases, 11th Revision).
Statistical Analysis
A sample size of 540 participants was prespecified for the trial,
assuming that 100% of participants in the usual care group,
and 96% of those in the medication reduction group would
have systolic blood pressure lower than 150 mm Hg at 12-week
follow-up. Calculations assumed a 0.90 noninferiority mar-
gin, 90% power, 2.5% 1-sided level of significance, 10% loss
to follow-up, and a 10% dilution effect due to crossover be-
tween groups. Due to the lack of evidence defining noninfe-
riority, the margin of 0.90 was chosen to inform future
physician-patient discussions about medication reduction; un-
der these assumptions, if noninferiority was demonstrated, it
would suggest that for every 10 patients who have their medi-
cation reduced, 9 would still have controlled blood pressure
at 12-week follow-up.
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The primary analysis population was defined as all par-
ticipants for whom data were available, and participants
were analyzed according to groups to which they were ran-
domly allocated, regardless of deviation from protocol. The
prespecified analysis for the primary outcome planned a
generalized linear mixed-effects model with baseline sys-
tolic blood pressure as a fixed effect and primary care site as
a random effect. However, due to convergence problems at
the time of analysis, we omitted site from the model and fit-
ted a robust Poisson regression model adjusting for baseline
systolic blood pressure. In addition, to account for missing
data in the analysis, a logistic regression model was used to
explore associations between baseline characteristics and
availability of the primary outcome. Covariates found to be
related to missingness were adjusted in the primary analy-
sis, including sex, Montreal Cognitive Assessment score,
EQ-5D-5L Index, and the Frailty Index. Six missing baseline
EQ-5D-5L scores and 10 missing baseline EQ-5D VAS scores
were replaced with the overall mean of respective variables
at baseline. Model diagnostics were checked and satisfied
(eFigure 3 in Supplement 3). Noninferiority was assumed if
the lower limit of the CI around the adjusted relative risk
(RR) of participants with controlled blood pressure was
above 0.90. Adjusted risk differences (RDs) were also calcu-
lated and reported using a robust Poisson model with iden-
tity link function.
Secondary analyses used descriptive statistics to exam-
ine the proportion of participants in the intervention group who
maintained medication reduction throughout the 12-week
follow-up period (overall and by drug class). Further analyses
comparing the adjusted mean difference in change in blood
pressure, antihypertensive medications, quality of life (esti-
mated from the EQ-5D-5L using the crosswalk value set),26
frailty, and health resource use at 12 weeks were analyzed by
means of linear mixed-effects models, adjusting for the base-
line level of the outcome and baseline systolic blood pres-
sure, with primary care site fitted as a random effect. The dif-
ference in adverse effects and serious adverse events between
the intervention and usual care groups was analyzed using a
robust Poisson model with adjustment for baseline systolic
blood pressure; site was not included in the model for the same
reason as the analysis of the primary outcome.
A per-protocol analysis of the primary outcome was per-
formed, excluding patients from the intervention group
who did not reduce treatment or who had medication rein-
stated during follow-up (although this latter action was part
of the medication reduction protocol). A post hoc analysis
of mean difference in change in blood pressure between
groups, corrected for baseline, was performed in the per-
protocol population. Prespecified subgroup analyses of
systolic blood pressure control, change in systolic blood
pressure, and maintenance of medication reduction were
conducted by different levels of baseline frailty, functional
independence, cognitive function, number of medications,
and number of comorbidities. Each potential moderator was
dichotomized, and an interaction term with treatment
group was fitted to the primary and secondary analysis
models to obtain the P value for interaction. Post hoc sub-
group analyses by baseline systolic blood pressure were per-
formed for the RR of systolic blood pressure control, main-
tenance of medication reduction, and mean difference in
change in blood pressure at 12-week follow-up. Further post
hoc analyses examined the primary outcome (systolic blood
pressure control) defined as below 140 mm Hg and below
130 mm Hg.
Sensitivity analyses of the primary outcome were under-
taken to examine missing data and outlying systolic blood pres-
sure values. Significance thresholds were set at 2.5% (1-sided)
for noninferiority and 5% (2-sided) for superiority. Because of
potential for type I error due to multiple comparisons, find-
ings for analyses of secondary end points should be inter-
preted as exploratory. All data were analyzed using Stata
version 15.1 (StataCorp).
Results
A total of 69 primary care sites participated from Central and
Southern England. Between March 20, 2017, and September
30, 2018, 6194 patients were invited by post to participate in
the trial, and 739 attended a screening appointment (Figure).
Of these, 569 participants (77.0%) provided informed con-
sent and were randomized. The characteristics of partici-
pants in the trial were broadly similar to those of the general
population (eTable 3 in Supplement 3).
Two hundred eighty-two participants (49.6%) were ran-
domized to the medication reduction intervention and 287 par-
ticipants (50.4%) were randomized to usual care (Figure). Fol-
low-up was completed on January 9, 2019, and the study
database was locked on May 23, 2019. Data on the primary out-
come were available in 534 participants (Figure). Participants
were well matched for all variables at baseline (Table 1; eTable 4
in Supplement 3).
Primary Outcome
Overall, 229 (86.4%) patients in the medication reduction
group and 236 (87.7%) patients in the usual care group had a
systolic blood pressure lower than 150 mm Hg at 12-week
follow-up (adjusted RR, 0.98 [97.5% CI, 0.92 to ]; Table 2).
The 97.5% 1-sided CI for this adjusted RR was greater than
0.9, indicating that medication reduction was noninferior to
usual care. These findings were robust to sensitivity analy-
ses examining the effect of missing data and outlying blood
pressure values (eTable 5 in Supplement 3). Results were
not materially different in the per-protocol population
(Table 2).
Secondary Outcomes
Medication reduction was maintained in 187 (66.3%) partici-
pants in the intervention group (eTable 6 in Supplement 3).
Mean (SD) systolic blood pressure at baseline was 129.4
(13.1) mm Hg in the medication reduction group and 130.5
(12.3) mm Hg in the usual care group (Table 1). At 12
weeks, mean systolic blood pressure was 133.7 (95% CI,
131.7 to 135.6) mm Hg in the medication reduction group and
130.8 (95% CI, 128.9 to 132.7) mm Hg in the usual care group,
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meaning that the change in systolic blood pressure at 12 weeks
was 3.4 mm Hg (95% CI, 1.0 to 5.8 mm Hg; Table 3) higher in
the medication reduction group compared with usual care af-
ter correcting for baseline blood pressure. Mean (SD) diastolic
blood pressure at baseline was 68.4 (9.1) mm Hg in the medi-
cation reduction group and 70.1 (8.4) mm Hg in the usual care
group (Table 1), and at 12 weeks, it was 70.9 (95% CI, 69.6 to
72.1) mm Hg in the medication reduction group and 69.7 (95%
CI, 68.5 to 70.8) mm Hg in the usual care group. The adjusted
mean difference in change in diastolic blood pressure cor-
rected for baseline was 2.2 mm Hg (95% CI, 0.9 to 3.6 mm Hg).
There were no statistically significant differences between
groups in frailty, quality of life (Table 3), adverse effects, or se-
rious adverse events at follow-up (Table 4).
Figure. Recruitment, Randomization, and Analysis Population
6194 Participants screened from medical records
and invited to attend baseline visita
739 Attended baseline visit
5455 Excluded
4970 Did not respond to invitation or declined
485 Found to be ineligible at telephone screening or unable to attend
appointment prior to end of study recruitment
170 Excluded
67 Clinic SBP >150 mm Hg
33 Not prescribed 2 or more antihypertensives for ≥12 mo prior to trial entry
28 Did not give informed consent or declined essential study procedures
20 Medically at risk as determined by primary care physician
12 Medication continued as determined by primary care physician
4 Heart failure due to left ventricular systolic dysfunction
2 Not on stable dose of antihypertensives for 4 wk
2 Blood pressure managed outside of primary care
1 Myocardial infarction within last 12 mo










4 Lost to follow-up
185 Included in the per-protocol
analysis
282 Randomized to medication reduction
282 Received usual care as
randomized
287 Randomized to receive usual care
287 Received usual care as
randomized
265 Included in the primary analysis 269 Included in the primary analysis





265 Measured at 12-wk follow-up
(primary outcome)
269 Measured at 12-wk follow-up
(primary outcome)
a Participants were required to be aged 80 years or older with controlled
systolic blood pressure at baseline (<150 mm Hg) and prescribed 2 or more
antihypertensive treatments for at least 12 months. Patients with a history of
heart failure due to left ventricular dysfunction or myocardial infarction or
stroke in the preceding 12 months, secondary hypertension, or lacking in
capacity to consent were excluded.
b Participants were allocated to one of the 2 study groups using a
nondeterministic minimization algorithm, minimized for site and baseline
systolic blood pressure. The first 3 participants were allocated using simple
randomization with subsequent participants allocated with a probability at 0.8
to ensure balance across the groups.
c A notes review was conducted in a further 25 patients (11 in the medication
reduction group and 14 in the usual care group) who did not attend 12-week
follow-up to obtain data available in the electronic health record (eg, medical
history, prescriptions).
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Age, mean (SD), y 84.6 (3.3) 85.0 (3.5)
>85 y 131 (46.5) 143 (49.8)
Women 131 (46.5) 145 (50.5)
Men 151 (53.5) 142 (29.5)
BMI, mean (SD)b 27.2 (4.2) [n = 270] 28.0 (4.3) [n = 264]
Underweight, BMI<18.5 1 (0.4) 2 (0.8)
Normal, BMI ≥18.5 to ≤30 213 (78.9) 183 (69.3)
Overweight, BMI>30 56 (20.7) 79 (29.9)
Race/ethnicityc
White 278 (98.6) 278 (96.9)
Other 4 (1.4) 9 (3.1)
Undergraduate or postgraduate degree obtained 44 (15.6) 39 (13.6)
Current smoker 3 (1.1) 5 (1.7)
Reported alcohol consumption every week 98 (34.8) 108 (37.6)
Total cholesterol, mean (SD), mmol/Ld 177.6 (46.3) [n = 252] 177.6 (46.3) [n = 259]
Estimated GFR, mean (SD), mL/min per 1.73 m2 61.6 (14.9) [n = 241] 60.4 (14.2) [n = 252]
Montreal Cognitive Assessment, mean (SD), scoree 24.4 (3.6) [n = 280] 24.0 (4.1) [n = 282]
EQ-5D-5L index, mean (SD), scoref 0.78 (0.17) [n = 279] 0.76 (0.17) [n = 284]
Modified Rankin Score >2g 36 (13.5) [n = 267] 42 (15.4) [n = 273]
Frailty
Morley FRAIL scale, mean (SD)h 0.77 (0.99) 0.95 (1.07)
0 155 (55.0) 134 (46.7)
1 58 (20.6) 68 (23.7)
2 50 (17.7) 55 (19.2)
3 17 (6.0) 26 (9.1)
4 2 (0.7) 4 (1.4)
Frailty index, mean (SD)i 0.14 (0.07) 0.15 (0.07)
Electronic Frailty indexj 0.14 (0.07) 0.15 (0.07)
Mean (SD)
Fit 121 (42.9) 109 (38.0)
Mild 132 (46.8) 143 (49.8)
Moderate 27 (9.6) 32 (11.1)
Severe 2 (0.7) 3 (1.0)
Blood pressure
Systolic, mean (SD), mm Hg 129.4 (13.1) 130.5 (12.3)
Diastolic, mean, (SD), mm Hg 68.4 (9.1) 70.1 (8.4)
History of high blood pressure, mean (SD), y 16.8 (8.9) [n = 269] 16.3 (9.0) [n = 276]
Standing systolic blood pressure, mean (SD), mm Hg 128.7 (15.5) [n = 264] 131.8 (16.2) [n = 261]
Orthostatic hypotensionk 15 (5.7) [n = 264] 10 (3.8) [n = 261]
Medical historyl
Chronic kidney disease 83 (29.4) 103 (35.9)
Cancer 67 (23.8) 68 (23.7)
Cardiac diseasem 61 (21.6) 61 (21.3)
Diabetes 48 (17.0) 53 (18.5)
Atrial fibrillation 45 (16.0) 45 (15.7)
Transient ischemic attack 27 (9.6) 22 (7.7)
Stroke 23 (8.2) 22 (7.7)
Peripheral vascular disease 6 (2.1) 9 (3.1)
No. of morbidities, mean (SD)l 5.7 (2.7) 6.0 (2.9)
No. with ≥ 2 morbiditiesl 278 (98.6) 282 (98.3)
(continued)
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Subgroup Analyses
There were no statistically significant interactions between the
randomized group and prespecified subgroups in systolic blood
pressure control, change in blood pressure, or maintenance of
medication reduction by subgroups (eFigures 4 and 5 and
eTable 6 in Supplement 3).







Antihypertensive 282 (100.0) 287 (100.0)
ACE inhibitor/angiotensin II receptor blockern 238 (84.4) 243 (84.7)
Calcium channel blockern 199 (70.6) 191 (66.6)
β-blockern 112 (39.7) 116 (40.4)
Thiazide and related diureticsn 109 (38.7) 111 (38.7)
Statin 97 (34.4) 92 (32.1)
Antiplatelet 58 (20.6) 53 (18.5)
Total antihypertensives, median (IQR) 2 (2-3) 2 (2-3)
Total noncardiovascular medications, median (IQR) 1 (1-2) 1 (1-2)
Total prescribed medications, median (IQR) 4 (3-7) 4 (3-7)
Abbreviations: BMI, body mass index; EQ-5D-5L, EuroQoL 5 Dimensions
5 Levels questionnaire; GFR, glomerular filtration rate; IQR, interquartile range.
SI conversion factor: To convert cholesterol to mmol/L, multiply by 0.0259.
a Values are reported as No. (%) unless otherwise indicated.
b Calculated as weight in kilograms divided by height in meters squared.
c Ethnic group was defined according to each participant’s self-reported
ethnicity, using Office for National Statistics categories.19 Those identifying as
white British or white other were classified as white; all other participants were
classified as nonwhite/unknown (termed as other)—4 in the medication
reduction group (1 African, 2 Caribbean, 1 unknown) and 9 in the usual care
group (1 Indian, 1 Pakistani, 1 Chinese, 1 Asian other, 1 Caribbean,
2 black/African/Caribbean, 2 unknown).
d Most recently recorded reading from electronic health records.
e Score ranges between 0 and 30 with lower scores representing greater
impairment. A score of 26 or greater is considered to be normal.
f The EQ-5D-5L assesses 5 aspects of health: mobility, self-care, activities,
discomfort, and anxiety/depression. EQ-5D-5L index scores were generated
using crosswalk approach, which translates the scores for the 5 EQ-5D-5L
items into a single index value. The index value ranges from −0.594 (worse
than death) to 1 (full health).
g Modified Rankin Score ranges from 0 (no symptoms), 1 (no significant
disability, able to carry out prestroke activities), 2 (slight disability, unable to
carry out prestroke activities but able to look after self without daily help),
3 (moderate disability, requiring some external help but able to walk without
assistance of another individual), 4 (moderately severe disability; unable to
walk or attend to bodily functions without assistance of another individual), to
5 (severe disability; bedridden, incontinent, requires continuous care).27
h Morley FRAIL scale consists of 5 components (fatigue, resistance, ambulation,
weight-loss, and illness), and ranges from 0 (fit) to 4 (frail).
i The Frailty index includes 54 items and ranges from 0 (fit) to 1 (frail).
j The Electronic Frailty Index has 36 items and is estimated from electronic
health records. The index ranges from 0 to 1 (fit, 0-0.12; mild, >0.12-0.24;
moderate, >0.24-0.36; severe, >0.36-1.0).
k Orthostatic hypotension is defined as a decrease in systolic blood pressure of
at least 20 mm Hg within 3 minutes of standing.28
l Individual conditions listed represent the 8 most common, thought to be
associated with high blood pressure. Conditions recorded and included in the
total morbidity count are listed in eTable 2 in Supplement 3. These included 49
conditions relating to cardiovascular disease and risk factors and also chronic
diseases and conditions resulting in physical and cognitive impairment.
mCardiac disease is defined as the presence of myocardial infarction, coronary
heart disease, angina, or heart failure.
n The sum of percentages for all antihypertensive medication classes may
exceed 100% since participants had to be taking more than 1 antihypertensive
medication to be eligible for the trial.
Table 2. Primary Outcome Difference in the Proportion of Patients With Clinically Acceptable Systolic Blood Pressure
Lower Than 150 mm Hg at 12 Weeks
Group, No. (%) RD, % (97.5% 1-sided CI) RR (97.5% 1-sided CI)a
P valuec
Medication
reduction Usual care Unadjusted Adjustedb Unadjusted Adjustedb
Primary analysis, No. 265 269
SBP <150 mm Hg 229 (86.4) 236 (87.7) −1.3 (−7.0 to ) −1.5 (−7.4 to ) 0.98 (0.92 to ) 0.98 (0.92 to ) .01
Per-protocol analysis, No.d 185 269
SBP <150 mm Hg 161 (87.0) 236 (87.7) −0.7 (−6.9 to ) −1.6 (−8.1 to ) 0.99 (0.92 to ) 0.98 (0.92 to ) .007
Abbreviations: EQ-5D-5L, EuroQoL 5 Dimensions 5 Levels questionnaire;
RD, risk difference; RR, relative risk; SBP, systolic blood pressure.
a The margin for noninferiority was set at 0.90 for RR. A lower bound of the CI
that did not exceed this margin indicated noninferiority.
b Indicates adjustment for baseline SBP, sex, cognitive function (Montreal
Cognitive Assessment score), and EQ-5D-5L Index and Frailty Index (both of
which were predictive of missingness, eTable 13 in Supplement 3).
c Indicates a P value for noninferiority for adjusted RR.
d A total of 187 participants maintained medication reduction. However,
2 did not have blood pressure measured at follow-up and therefore were
excluded from the per-protocol analysis. Of those who did have blood
pressure measured (n = 265), 80 participants were not taking fewer
medications at follow-up and therefore were excluded from the per-protocol
analysis. Sixty-six of these 80 participants had medications reinstated during
follow-up based on the study safety monitoring algorithm (eFigure 2 in
Supplement 3).
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Post Hoc Outcomes
Three participants in the intervention group did not reduce
medications while 2 increased treatment (eTable 7 in Supple-
ment 3). Participants in the medication reduction group were
taking 0.6 fewer antihypertensive medications than the usual
care group at 12-week follow-up (Table 3). A total of 101 partici-
pants (38.1% [95% CI, 32.2% to 44.2%]) in the medication re-
duction group had no increase in systolic blood pressure at 12-
week follow-up vs 64 participants (34.6% [95% CI, 27.8% to
41.9%]) in the per-protocol population (eFigure 6 in Supple-
ment 3). When analyses were restricted to those patients who
maintained medication reduction throughout follow-up (per-
protocol population), a greater increase in systolic and diastolic
blood pressure was seen in the intervention group (Table 3).
There was no statistically significant difference in systolic blood
pressure control or mean difference in blood pressure by base-
line systolic blood pressure level (eFigures 4 and 5 in Supple-
ment 3). There was no statistically significant difference in main-
tenance of medication reduction by baseline blood pressure
(eTable 8 in Supplement 3). However, the RR of blood pressure
control was reduced when thresholds defining control were re-
duced to lower than 150 mm Hg (eTable 9 in Supplement 3).
The number of patients experiencing at least 1 adverse
event was significantly higher in the medication reduction
group (adjusted RR, 1.28 [95% CI, 1.06 to 1.54]; Table 4). A total
of 65 (27% of those occurring in the intervention group) ad-
verse events were considered possibly related to withdrawal
of treatment. More adverse events related to the circulatory
system were reported in the medication reduction group, but
this was not observed for serious cardiovascular events
(eTables 10 and 11 in Supplement 3). Participants in the medi-
cation reduction group attended significantly more health care
appointments during follow-up than the usual care group
(eTable 12 in Supplement 3).
Discussion
In this noninferiority randomized clinical trial among older pa-
tients treated with multiple antihypertensive medications, a
strategy of antihypertensive medication reduction, com-
pared with usual care, demonstrated noninferiority with re-
gard to the proportion of patients with systolic blood pres-
sure lower than 150 mm Hg at 12 weeks. However, systolic blood
pressure was increased in the medication reduction group, and
therefore, potential benefits of reducing medication need to
be balanced against possible harms from increased risk of car-
diovascular disease in the longer term.
In contrast with the present study, previous antihyperten-
sive deprescribing trials have only attempted medication
Table 3. Secondary Outcomes and Post Hoc Outcomes at 12 Weeks
Medication reduction group Usual care group
Adjusted mean difference
(95% CI) P valuea
No.
analyzed Mean (95% CI)
No.
analyzed Mean (95% CI)
SBPb,c 265 133.7 (131.7 to 135.6) 269 130.8 (128.9 to 132.7) 3.4 (1.0 to 5.8) .005
DBPb,d 265 70.9 (69.6 to 72.1) 269 69.7 (68.5 to 70.8) 2.2 (0.9 to 3.6) .001
Quality of life at 12 weekse,f
EQ-5D-5L index 260 0.79 (0.77 to 0.81) 263 0.79 (0.77 to 0.81) −0.01 (−0.03 to 0.01) .50
EQ-5D-5L VAS 259 78.5 (76.6 to 80.4) 259 78.3 (76.5 to 80.1) −0.76 (−2.86 to 1.33) .47
Frailty at 12 weekse,f
Frailty index 282g 0.137 (0.130 to 0.145) 287g 0.145 (0.136 to 0.152) −0.00003 (−0.005 to 0.005) .77
Electronic frailty index 278g 0.134 (0.126 to 0.141) 285g 0.140 (0.132 to 0.148) 0.001 (−0.003 to 0.005) .77




185 134.4 (132.1 to 136.7) 269 130.8 (128.9 to 132.7) 4.9 (2.4 to 7.5) <.001
DBP (per-protocol analysis,
mm Hg)d,h
185 71.6 (70.2 to 73.1) 269 69.7 (68.5 to 70.8) 3.4 (1.8 to 4.9) <.001
Change in antihypertensive
prescriptions
276g −0.68 (−0.74 to −0.61) 283g −0.05 (−0.08 to −0.01) −0.63 (−0.70 to −0.56) <.001
Abbreviation: DBP, diastolic blood pressure; EQ-5D-5L, EuroQoL 5 Dimensions
5 Levels questionnaire; SBP, systolic blood pressure; VAS, visual analog scale.
a P values are given for superiority, in contrast to Table 2 (in which they are given
for noninferiority).
b Analyses conducted in the primary analysis population (all available
participants) unless otherwise stated.
c Adjusted for baseline SBP, sex, cognitive function (Montreal Cognitive
Assessment score), and EQ-5D-5L Index and Frailty Index (both of which were
predictive of missingness, eTable 13 in Supplement 3) with a random effect for
primary care site.
d Adjusted for baseline SBP and DBP, sex, cognitive function Montreal Cognitive
Assessment score, and EQ-5D-5L Index and Frailty Index (both of which were
predictive of missingness, eTable 13 in Supplement 3) with a random effect for
primary care site.
e Adjusted for baseline level of the outcome; baseline SBP fitted as a fixed
effect. Six missing baseline EQ-5D-5L scores and 10 missing baseline EQ-5D
VAS scores were replaced with the overall mean of the covariate
at baseline.
f See Table 1 for definitions of quality of life and frailty indices. The EQ-5D-5L
VAS has values between 0 (worst health) and 100 (best health).
g The number analyzed includes all participant for whom data could be collected
from the electronic health record and therefore exceeds the numbers (265
and 269) who underwent 12-week face-to-face follow-up.
h The per-protocol population excluded patients from the intervention group
who did not reduce treatment or who had medication reinstated during
follow-up as part of the safety algorithm (although this latter action was part
of the medication reduction protocol).
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reduction in 32% to 68% of participants,29-31 had smaller
sample sizes,29,30 examined younger populations,31 and lacked
comparisons with a control group to determine the effect of
deprescribing on outcomes.29 Longer-term studies do exist,
but these are observational in nature and do not include a con-
trol group for robust comparison of outcomes.32 In all but 1 pre-
vious trial,30 medication reduction was part of a medication
review but not specifically mandated, and patients could have
only been taking a single antihypertensive at trial entry.29,31,33-35
Mandating medication reduction in this trial, while ensuring
all participants continued some antihypertensive treatment,
may have reduced clinical inertia by the treating physician com-
pared with previous work.36,37
The only other trial that has examined the effect of anti-
hypertensive medication reduction on blood pressure in
older patients examined individuals prescribed fewer anti-
hypertensives (61.5% vs 100% prescribed ≥2 medications)
but with higher baseline blood pressure (148/81 mm Hg vs
130/69 mm Hg).30 Initial medication reduction was achieved
in 67.8% of participants, but the number having therapy
reinstated at 16-week follow-up was not reported. Medica-
tion reduction in that trial resulted in a larger increase in sys-
tolic blood pressure (7.4-mm Hg increase in all patients
available for analysis and 11.1-mm Hg increase in the per-
protocol population) than was observed in the present study.
This is likely due to the medication reduction algorithm
used, in which antihypertensive medications were itera-
tively stopped until a maximum increase in systolic blood
pressure of 20 mm Hg was reached.
Proponents of deprescribing suggest potential benefits
could be an increased quality of life, reduced adverse effects,
and a reversal of cognitive decline.15,30 However, these poten-
tial benefits might be expected to happen over the longer term
and are yet to be demonstrated in robust randomized clinical
trials. This study was unable to demonstrate short-term ben-
efits but was not powered to detect significant differences in
adverse effects or quality of life. These should be studied in a
longer-term context.
This trial described a structured approach to antihyper-
tensive medication reduction and provides evidence
relevant to routine clinical practice. It showed that antihy-
pertensive medication reduction can be achieved (in the
Table 4. Most Commonly Reported Adverse Effects, Adverse Events, and Serious Adverse Events
Medication





Adverse effects, No.b 264 266
Stiff joints 124 (47.0) 130 (48.9) 5.1 (−3.3 to 13.4) 1.05 (0.89 to 1.23)
Pain 108 (40.9) 124 (46.6) −3.7 (−12.1 to 4.6) 0.90 (0.75 to 1.08)
Fatigue 107 (40.5) 119 (44.7) −4.6 (−12.8 to 3.6) 0.93 (0.78 to 1.11)
Loss of strength 77 (29.2) 95 (35.7) −5.6 (−13.2 to 1.9) 0.81 (0.64 to 1.01)
Breathlessness 77 (29.2) 88 (33.1) −2.1 (−8.8 to 4.6) 0.96 (0.77 to 1.20)
Sleep difficulties 77 (29.2) 85 (32.0) −0.4 (−7.4 to 6.6) 0.97 (0.77 to 1.22)
Pins and needles 78 (30.0) 65 (24.4) 2.8 (−2.9 to 8.6) 1.20 (0.93 to 1.51)
Sore eyes 57 (21.6) 72 (27.1) −5.5 (−12.1 to 1.0) 0.89 (0.67 to 1.17)
Dizziness 54 (20.5) 57 (21.4) −3.2 (−2.7 to 9.1) 1.08 (0.80 to 1.46)
Impotence 47 (17.8) 53 (20.0) −2.1 (−7.0 to 2.9) 0.93 (0.70 to 1.24)
≥1 Reported adverse effect 234 (88.6) 246 (92.5) −3.5 (−8.6 to 1.5) 0.96 (0.91 to 1.02)
No. of adverse effects,
median (IQR)
4 (2 to 6) 4 (2 to 7)
Adverse events, No.c 282 287
≥1 Reported adverse eventc,d 139 (49.3) 113 (39.4) 10.0 (1.9 to 18.1) 1.28 (1.06 to 1.54)
No. of adverse events,
median (IQR)
0 (0 to 1) 0 (0 to 1)
≥1 Reported serious
adverse evente
12 (4.3) 7 (2.4) 1.6 (−1.3 to 4.5) 1.72 (0.68 to 4.29)
Abbreviation: IQR, interquartile range.
a Adjusted for baseline systolic blood pressure and baseline adverse effects for
adverse effect outcomes. The reporting of adverse effects and adverse events
involved classifying the number into a binary variable in which 0 indicates no
reported adverse effect or event and 1 indicates at least 1 reported adverse
effect or event.
b Ten most commonly reported adverse effects listed as measured by the
Revised Illness Perception Questionnaire for Hypertension.25 The
denominator in each group reflects the number of participants completing this
questionnaire at follow-up.
c Adverse events were those reported by the participant or observed by the
investigator during trial follow-up, which were then assessed for relatedness
by the local primary care physician and did not result in hospitalization
or death.
d Post hoc outcome not included in protocol or statistical analysis plan and
specified after seeing initial results.
e Serious adverse events were those reported by the treating physician during
trial follow-up, defined as those resulting in death or considered life
threatening, required inpatient hospitalization or prolonged existing
hospitalization, resulted in persistent or significant disability/incapacity or
other medical events considered to be serious because they jeopardized the
participant or required intervention to prevent one of the above
consequences. The number of serious adverse events are reported as follows
(per intervention group; control group): hospitalization (2; 4), fall (2; 1), acute
coronary syndrome (1; 0), arrhythmia (1; 0), gastrointestinal hemorrhage
(1; 0), hip arthroplasty (1; 0), inguinal hernia repair (1; 0), ischaemic stroke
(1; 0), myocardial infarction (0; 1), peripheral ischemia (0; 1), pneumonia (1; 0),
sepsis (0;1), somnolence (1; 0), transurethral bladder resection (1; 0), urinary
tract infection (0; 1) and wound dehiscence (0; 1).
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short-term) in some patients with multimorbidity and poly-
pharmacy, who were selected by their primary care physi-
cian to potentially benefit from medication reduction. Of
those following the medication reduction and monitoring
algorithms, a similar proportion had systolic blood pressure
lower than 150 mm Hg at follow-up compared with those
not reducing medication, and two-thirds were taking fewer
antihypertensive medications after 12 weeks. This resulted
in participants in the medication reduction group taking 0.6
fewer antihypertensives than those not reducing medica-
tion at follow-up. This reduction was modest, and further
studies should explore whether greater medication reduc-
tion (ie, removal of multiple medications) can be achieved
without affecting blood pressure control at follow-up.
Previous trials of blood pressure lowering in older
adults (such as SPRINT and the Hypertension in the Very
Elderly Trial)3,4,38 do not represent frail patients with multi-
morbidity who may be at higher risk of adverse events from
polypharmacy.6,7 As a result, there is divergence in interna-
tional guidelines as to what is an appropriate target for blood
pressure in people older than 80 years. The UK National Insti-
tute for Health and Care Excellence (updated in 2019)11 and
the US American College of Physicians/American Academy of
Family Physicians (2017)39 define the threshold for systolic
blood pressure control as lower than 150 mm Hg—the thresh-
old used in this study. In contrast, American Heart Association/
American College of Cardiology guidelines40 now recom-
mend a target of 130 mm Hg (where tolerated), primarily based
on the findings of the SPRINT trial.4,38 What this trial has shown
is that withdrawal of a blood pressure agent is associated with
a small rise in blood pressure in patients older than 80 years
with multimorbidity, mild frailty, polypharmacy, or a combi-
nation of these characteristics. The threshold at which such
medication reduction is contemplated will depend on the
guideline being used. Post hoc analyses of the current study
suggested that lower thresholds for blood pressure control
would have resulted in worse control from drug withdrawal,
presumably because primary care physicians were less likely
to reintroduce therapy at such lower thresholds because this
was not specified in the study protocol.
Although the patient population in this study was gener-
alizable to primary care, this trial did not establish whether or
not medication reduction should be attempted (in terms of
clinical outcomes) or who should be targeted with such an in-
tervention. The 3.4-mm Hg increase in systolic blood pres-
sure and the 2.2-mm Hg increase in diastolic blood pressure
observed following medication reduction suggest caution
should be exercised when adopting this approach in routine
clinical practice. Studies in populations with less multimor-
bidity have suggested that medication reduction might not re-
sult in an increase in cardiovascular events, provided blood
pressure remains controlled, although this was attributed to
greater use of nonpharmacological interventions.41 It is un-
clear whether an increased risk of cardiovascular disease is as
important in an older population in which there are compet-
ing risks from other conditions.
Deprescribing of antihypertensive drugs (and other medi-
cations) is increasingly being promoted in clinical guidelines13,14
and clinical care,15 despite a lack of robust evidence from ran-
domized clinical trials. This study is an important step to ad-
dressing this evidence gap and highlights the short-term ef-
fects, which could be important to informing decision making
between patients and physicians considering antihyperten-
sive medication reduction. Future trials should explore the
long-term effects of medication reduction, particularly focus-
ing on frailer patients with multimorbidity who have not been
studied in previous trials.3,4,38
Limitations
This study has several limitations. First, participants were se-
lected based on the primary care physician’s view that they
might benefit from medication reduction, and approxi-
mately 1 in 10 of those invited by post were enrolled. Despite
this, included participants were representative of the general
population in primary care in terms of age and blood pres-
sure, with similar levels of morbidity and frailty (eTable 3
Supplement 3). The trial was designed to minimize bias using
a web-based randomization algorithm and allocation conceal-
ment prior to consent and choice of medication to reduce.
Follow-up was achieved in 94% of participants, limiting the
likelihood of attrition bias.
Second, the unblinded design meant patients and inves-
tigators were aware of the treatment allocation and study end
points. However, blood pressure measurement was under-
taken using an automatic sphygmomanometer, which re-
quired minimal input from the investigator, and therefore, the
potential for bias in ascertainment of the primary outcome was
low. Knowledge of taking fewer medications may have led par-
ticipants in the medication reduction group to report fewer ad-
verse effects at follow-up, but no significant differences be-
tween groups were observed.
Third, participants in the medication reduction group
attended at least 1 additional appointment during follow-up
(the 4-week safety visit) compared with usual care, explain-
ing most of the increased consultation rate. This may
also explain the significantly higher incidence of adverse events
seen in this group, particularly given that only one-fourth
of the events were considered possibly related to medica-
tion reduction.
Fourth, 13 participants in the usual care group reduced their
antihypertensive medication during follow-up. We did not ro-
bustly measure whether individuals were adherent to their re-
maining medications in either group, and this could have af-
fected the proportion of participants with systolic blood
pressure lower than 150 mm Hg at follow-up.
Fifth, the decision to design the trial with a short period of
follow-up (12 weeks) was made for ethical reasons to demon-
strate the short-term effects of medication reduction on blood
pressure and adverse events prior to embarking on a larger study
with longer follow-up. This meant the study was underpow-
ered to make reliable comparisons of adverse events between
groups, and as a result, the long-term benefits and harms of an-
tihypertensive medication reduction remain unknown.
Sixth, the noninferiority margin was determined based on
opinion of likely meaningfulness for physician and patient dis-
cussions and not prior evidence.
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Conclusions
Among older patients treated with multiple antihypertensive
medications, a strategy of antihypertensive medication re-
duction, compared with usual care, was noninferior with regard
to the proportion of patients with systolic blood pressure lower
than 150 mm Hg at 12 weeks. The findings suggest antihyper-
tensive medication reduction can be achieved without sub-
stantial change in blood pressure control in some older pa-
tients with hypertension, although further research is needed
to understand long-term clinical outcomes.
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(Peter Grimwade), 27 Beaumont Street Medical
Practice (Richard McManus), Botley Medical Centre
(Mary Akinola), Broadshires Health Centre
(Christine A'Court), The Cedars Surgery (Clare
Nieland), Cookham Medical Centre (Kenney Tsoi),
Church Street Practice (Matthew Gaw), Eynsham
Medical Group (Ian Binnian), Hughenden Valley
Surgery (Lynette Hykin), Hollow Way Medical
Practice (Debbie Goldman), Jericho Health Centre
(Mark O'Shea), King Edward Street Medical Practice
(Brian Nicholson), Magnolia House Surgery (Kavil
Patel), Medicas Health Limited (Ruth Mason),
Milman Road Surgery (Aneeka Bajwa), St Clements
Surgery (Hernandez), South Oxford Health Centre
(Nick Wooding), Summertown Health Centre (Kyle
Knox), Temple Cowley Medical Group (Elisabetta
Angeleri-Rand), Chalgrove and Watlington
Surgeries (Grace Ding), The Downland Practice
(Chloe Evans), The Ivers Practice (Neetul Shah),
Thatcham Medical Practice (Sarah Wadsworth),
Woodlands Medical Centre (Adam Jones),
Wokingham Medical Centre (Zishan Ali), Whaddon
Medical Centre (Asim Malik), White Horse Medical
Practice (Simon Cartwright), Homewell and Curlew
Practice (Helen Whiting), Liphook and Liss Surgery
(Anna Lalonde), Vine Medical Group (Olivia
Boocock), Wareham Surgery (James Bennett),
Badgerswood and Forest Surgery (Helen Sherrell),
Lordshill Health Centre (Faycal Elhani), Highcliffe
Medical Centre (Zelda Cheng), Cowplain Family
Practice (Nicola Millen), Blackthorn Health Centre
(Ali Shahsavanpour), Feltwell Surgery (Michael
Pullen), Bridge Street Surgery (Clare Hambling),
Little St John Street (Gary Taylor), Hoveton and
Wroxham Medical Practice (Carsten Dernedde),
Wansford and Kings Cliffe Practice (Amrit Takhar),
Woolpit Health Centre (Richard West), Shelford
Medical Practice (Chris Schramm), St Mary's
Surgery (Katrina Young), Bennfield Surgery (Nick
Doherty and Suparna Behura), West Heath Primary
Care Centre (Gulshan Arora), Westside Medical
Centre (Mark Lindsey), Eve Hill Medical Practice
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(David Shukla), River Brook Medical Centre,
(Naresh Chauhan), Park Leys Medical Practice
(Rachel Spencer), Manor Court Surgery (Farhana
Lockhat), The Marches Surgery (Crispin Fisher),
Winyates Health Centre (Vattakkatt Premchand),
Avonside Health Centre (Sarah Colliver), Hastings
House Surgery (Paul de Cates), Maypole Health
Centre (Soong Loy Yap), Eden Court Medical
Practice (Naresh Aggarwal), Old Priory Surgery
(Mark Grocutt), Courtside Surgery (Vicky Smith),
Trowbridge Health Centre (Toby Cookson), Phoenix
Surgery (Naomi Vernon), West Walk Surgery (Sam
Davies), Winchcombe Medical Centre (Richard
Tribley), Mann Cottage Surgery (Cathy Bobrow),
Chipping Campden Surgery (Rebecca Zamir).
Trial Steering Committee: Tom Robinson, MD
(Chair, University of Leicester; Rod Taylor, PhD,
University of Exeter; Richard Lindley, MD,
University of Sydney; Peter Bower, PhD, University
of Manchester; Ms Margaret Ogden (patient and
public involvement representative), Ms Anita
Higham (MEd, patient and public involvement
representative).
Data Monitoring Committee: John Gladman, MD,
Chair, University of Nottingham; Una Martin, PhD,
University of Birmingham; Martyn Lewis, PhD,
Keele University.
Disclaimer: The views expressed are those of the
author(s) and not necessarily those of the NIHR or
the Department of Health and Social Care.
Data Sharing Statement: See Supplement 4.
Requests for sharing of deidentified individual
participant data and a data dictionary defining each
field in the set will be considered by the
corresponding author.
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acknowledge the support of the Primary Care
Clinical Trials Unit; staff from the NIHR Clinical
Research Networks including Thames Valley and
South Midlands, Eastern, Wessex, West Midlands
(Central and South), and West of England; and Lucy
Curtin (University of Oxford) for administrative
support. Rebecca Lowe, BSc, Hannah Ashby, BSc,
and Hannah Swayze, PhD (University of Oxford);
Bethany Diment, PhD (University of Cambridge);
and Sarah Oliver, BA (University of Southampton)
worked as research facilitators recruiting and
following up participants. Alecia Nickless, PhD
(University of Oxford) assisted with the preparation
of trial steering committee, data monitoring and
ethics committee reports, and drafting of the
statistical analysis plan. Margaret Ogden and Anita
Higham (MEd) served as patient representatives for
the trial steering committee. Additional members of
the trial steering committee were Tom Robinson,
MD (committee chair; University of Leicester), Rod
Taylor, PhD (University of Exeter and University of
Glasgow), Richard Lindley, MD (University of
Sydney), and Peter Bower, PhD (University of
Manchester). Members of the data monitoring
committee were John Gladman, MD (committee
chair; University of Nottingham), Una Martin, PhD
(University of Birmingham), and Martyn Lewis, PhD
(Keele University). Individuals working as part of
the trial team were employed by coordinating
centres in the trial. Patient representatives were
compensated for their time spent attending trial
management and trial steering committee
meetings. All other members of the trial steering
and data monitoring committees gave their time
voluntarily and were only compensated for travel
expenses incurred by attendance at meetings.
Participating primary care physicians were
reimbursed for time and costs incurred working on
the trial. The authors thank the patients who
participated in this study.
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